CD44 and cancer: EGFR and MAPK signaling pathway components as well as the EMT transcription factor SLUG (SNAI2; [25, 28, 29]) or the putative cancer stem cell marker CD44 [23, 30] may be considered, at least partially, as effective cancer targets or surrogate biomarkers.